Search Options Stock News and Analysis from Schaeffer's

PBYI Stock Plunges After Goldman Screams "Sell"

https://www.schaeffersresearch.com/content/news/2019/10/08/pbyi-stock-plunges-after-goldman-screams-sell

10/8/2019 9:56 AM

Goldman Sachs downgraded Puma Biotechnology Inc (NASDAQ:PBYI) stock to "sell" from "neutral," and slashed its price target to $8 from $24 -- a 20.6% discount to last night's close. The brokerage firm...

Put Options In Play For This Drug Stock

https://www.schaeffersresearch.com/content/analysis/2019/09/05/put-options-in-play-for-this-drug-stock

9/5/2019 11:55 AM

The shares of Puma Biotechnology Inc (NASDAQ:PBYI) are enjoying a mini-rally today, up 3.1% to trade at $10.71 at last check. The drug stock has added 17% in the past month, but this has taken PBYI ri...

Dow Down Big Again; Uber IPO In Focus

https://www.schaeffersresearch.com/content/ezines/2019/05/10/dow-down-big-again-uber-ipo-in-focus

5/10/2019 11:55 AM

The Dow Jones Industrial Average (DJI) is down 300 points today following an increase in U.S. tariffs on Chinese goods and more tweeting this morning from President Donald Trump. Specifically, Pre...

Options Volume Spikes on Sinking Drug Stock

https://www.schaeffersresearch.com/content/options/2019/04/01/options-volume-spikes-on-sinking-drug-stock

4/1/2019 2:36 PM

The shares of Puma Biotechnology Inc (NASDAQ:PBYI) are down 9.3% to trade at $35.29, one of the worst stocks on the Nasdaq today, after the company inked an exclusive licensing deal with Pierre Fabre ...

Puma Biotechnology Attempts a Rebound After Drug Win

https://www.schaeffersresearch.com/content/news/2018/12/18/puma-biotechnology-attempts-a-rebound-after-drug-win

12/18/2018 10:33 AM

Shares of Puma Biotechnology Inc (NASDAQ:PBYI) are up 6.9% at $22.90, after the company announced successful results of the Phase III NALA trial for its experimental breast cancer drug, neratinib. An...

PEOPLE ALSO SEARCH FOR